首页|基于HSP90抑制剂BIIB021的硝基还原酶前药的设计、合成及潜在抗肿瘤活性评价

基于HSP90抑制剂BIIB021的硝基还原酶前药的设计、合成及潜在抗肿瘤活性评价

扫码查看
在BIIB021的基础上合成了一系列硝基还原酶(NTR)前药,作为潜在的抗癌剂,并在体外测试了其细胞毒性作用.结果表明:化合物1c和2c具有良好的抗肿瘤活性,IC50分别为0.72和1.12 μM.此外,与阳性母体化合物BIIB021相比,这两种化合物对正常细胞WI-38的毒性也较低(IC50=495.51和570.27 μM vs 261 μM).细胞周期测试分析表明:两种化合物都对HeLa细胞周期阻滞在G2/M期,同时G0/G1期的细胞数量减少,并诱导其凋亡.综上所述:化合物1c和2c具有潜在的抗肿瘤活性,有潜力作为先导化合物,用于进一步结构优化和体内验证研究.
Design,synthesis,and biological assessment of prodrugs for nitroreductase-based HSP90 inhibitor BIIB021:exploring their potential as anticancer agents
A series of prodrugs based on BIIB021,designed for nitroreductase(NTR),were synthesized and tested in vitro for their cytotoxic effects as potential anticancer agents.The results revealed that compounds 1c and 2c exhibited promising antitumor activity,with IC50 values of 0.72 and 1.12 μM,respectively.Notably,both compounds demonstrated lower toxicity to normal WI-38 cells compared to the positive control BIIB021(IC50=495.51 and 570.27 μM vs.261 μM).Cell cycle analysis indicated that both compounds induced cell cycle arrest in the G2/M phase,accompanied by a concomitant decrease in the population of the G0/G1 phase in HeLa cells,ultimately leading to apoptosis.These preliminary findings suggested that compounds 1c and 2c held the potential to serve as promising lead compounds for further structural optimization and in vivo validation studies.

Heat shock protein 90BIIB021NTRNitro benzamides

吴争荣、谢亲建、金鹏、张天峰、韩佳茜、贺殿

展开 >

兰州大学药学院,甘肃兰州 730000

甘肃武警医院药剂科,甘肃兰州 730000

热休克蛋白90 BIIB021 硝基还原酶 硝基苯甲酰胺

CAPF Self-Help Research,InnovationCAPF High-level Science and Technology Talent Development and Nova in Science

ZZKY20222046

2024

中国药学(英文版)
中国药学会

中国药学(英文版)

CSTPCD
影响因子:0.534
ISSN:1003-1057
年,卷(期):2024.33(1)
  • 33